Analysts expect the Cambridge, Massachusetts-based company to report a quarterly loss at $1.9 per share, versus a year-ago loss of $9.53 per share. Moderna projects to report revenue of $1.25 billion ...

Merck and Moderna initiate Phase 3 trial of mRNA-4157 (V940) with Keytruda as adjuvant for NSCLC patients, marking progress in individualized cancer therapies. Vandana Singh Benzinga Bulls And ...

Moderna, Inc. MRNA reported earnings of 3 cents per share in the third quarter of 2024. The Zacks Consensus Estimate was a ...

Moderna MRNA is set to report third-quarter 2024 earnings on Nov. 7, before the opening bell. The Zacks Consensus Estimate ...

The trial compared Moderna's MRNA-4157/V940 vaccine given alongside Merck & Co's cancer immunotherapy Keytruda (pembrolizumab) to Keytruda alone in patients with the skin cancer melanoma.

MSD – known as Merck & Co in the US and Canada – took up an option to partner with Moderna on V940 in October 2022, the first programme to be activated under a 2016 alliance between the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

At the Financial Times’ Global Pharma and Biotech Summit 2024, a breakout panel discussed how dealmaking remains vital for biopharma companies facing pipeline and revenue pressures. At the Financial ...

At the Financial Times’ Global Pharma and Biotech Summit 2024, a panel discussed ways to prepare for the high number of incoming patent expiries and how to protect key drugs.